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Sjögren’s syndrome (SS), a chronic autoimmune
inflammatory exocrinopathy and epithelitis, is
characterized by lymphocytic infiltration of dif-
ferent exocrine glands and epithelia, most notably
the salivary and lacrimal glands.1–3 The involve-
ment of exocrine glands in SS results in loss of
functional epithelium and diminished exocrine
secretory function leading to the typical features of
sicca syndrome, such as keratoconjunctivitis sicca
(dry eye), xerostomia (dry mouth) and dryness
of other body parts.3 tSS is one of the mos  
common autoimmune disorders3,4 and can mani-
fest either alone (primary SS) or in association
with almost all of the systemic rheumatic dis-
eases,5 most commonly rheumatoid arthritis6
and systemic lupus erythematosus.7
fTreatment goals for SS include palliation o
sicca symptoms, prevention of complications
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and proper intervention of extraglandular mani-
festations.3,8 Although the awareness of its sys-
temic nature and considerable morbidity has
directed treatments toward disease modification,
treatment of sicca symptoms with immunomod-
ulatory drugs has been unsuccessful.2,3,9,10 In
contrast, the use of tear or saliva substitutes may
provide transient relief of sicca symptoms, but
often fails to prevent ocular and dental compli-
cations.11,12 Hence, the use of secretagogues to
stimulate secretion from exocrine glands repre-
sents a novel approach to alleviate the sicca
symptoms of patients with SS.3,10,12
Pilocarpine, a natural plant alkaloid derived
from the South American shrub Pilocarpus jabo-
randi, is a cholinergic parasympathomimetic ago-
nist that stimulates muscarinic-M3 receptors of
various exocrine glands leading to increased se-
cretory function.13 Indeed, pilocarpine hydrochlo-
ride (Salagen®; MGI Pharma, Inc., Bloomington,
MN, USA) has been approved for the treatment of
radiation-induced dry mouth14,15 and SS.10,12,16 In
patients with primary or secondary SS, treatment
with pilocarpine may alleviate sicca symptoms
by increasing saliva flow. Controlled studies12,14
have also shown that pilocarpine is safe and well
tolerated, with no serious adverse effect or drug
interaction. As genetic predisposition and eth-
nicity affect the clinical manifestations and im-
munologic features of SS,17–19 differences in the
treatment responses to pilocarpine require investi-
gation in different populations. This double-blind,
randomized, placebo-controlled trial investigated
the clinical efficacy and safety of oral pilocarpine
5 mg four times daily for the improvement of
oral symptoms in patients with SS in Taiwan.
Methods
Patients
Patients older than 18 years with a diagnosis of
primary or secondary SS1 according to the 1993
American College of Rheumatology criteria were
enrolled from rheumatology outpatient clinics of
National Taiwan University Hospital (NTUH)
between April 1, 2002 and November 13, 2002.
rDiagnosis of primary SS in patients without othe
yrheumatic disorders required the presence of an
four of the following six criteria: ocular symp-
toms, oral symptoms, ocular signs, objective sali-
cvary gland involvement, abnormal histopathologi
feature of salivary glands, and the presence of an-
tinuclear antibodies, rheumatoid factors, autoan-
tibodies against Ro(SSA) or La(SSB) antigens.
Diagnosis of secondary SS1 was based on the find-
ing of a well-defined connective tissue disease
fwith ocular or oral symptoms, and the presence o
any two objective criteria among ocular signs,
salivary gland involvement and histopathology.
fPatients with a clinically significant history o
rcardiopulmonary, gastrointestinal, renal disease o
diabetes mellitus were excluded. In addition, pa-
tients with clinically significant ocular disease, such
as elevated intraocular pressure >20 mmHg, glau-
rcoma, uveitis or scleritis, preexisting retinopathy o
cretinal detachment, retrobulbar neuritis, herpeti
ulcer of cornea, or ocular cancer were excluded.
Women of childbearing potential were required to
use an acceptable method of contraception.
Treatment protocol
All participants underwent baseline medical and
ophthalmologic history taking, physical exami-
nation and electrocardiography (ECG) at the
screening visit. At the baseline visit (week 0), pa-
tients were randomly assigned to the pilocarpine
or placebo group using sealed randomization en-
velopes. The placebo was made identical in ap-
pearance to the active drug, and all tablets were
supplied by MGI Pharma Inc. Both investigators
and participants were tblinded to the treatmen
assignments. Participants were instructed to take
rone tablet of the study medication with wate
four times daily (qid) at mealtimes and bedtime
for 12 weeks, and to record missed doses and ad-
verse events in a diary. Participants returned to
the study site at weeks 6 and 12 for efficacy and
safety evaluations. At each visit, patients under-
went vital signs measurement and clinical labora-
tory examinations (urinalysis, complete blood cell
counts, electrolytes, liver and renal function tests),
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and reported their responses in the question-
naires. Medications (prescription or over the
counter) taken by study participants within 30
days prior to the screening date and changes in
medication were also recorded. Saliva secretion
was recorded at 60 minutes after taking the study
medication. Physical examination and medical
and ophthalmologic history taking were performed
again at the end of the study. The study was ap-
proved by the institutional review board of the
NTUH, and written informed consent was ob-
tained from all study participants.
Efficacy assessment
Treatment efficacy was assessed based on the pro-
portion of patients who indicated a beneficial re-
sponse on questionnaires and had increased saliva
production at weeks 6 and 12 compared to base-
line. Efficacy was compared by intention-to-treat
analysis using the last available postdose obser-
vation (i.e. end point) for each patient.
The primary outcome in this study was the
global improvement of dry mouth. Participants
were asked to indicate their overall condition of dry
mouth on a 100 mm visual analog scale (VAS) at
the week 6 and 12 visits compared with how they
felt at the beginning of the study. Responses on
the VAS were classified as follows: < 45 mm indi-
cated nonresponder (worse); 45–55 mm indicated
nonresponder (no change); and >55mm indicated
responder (improvement). For assessment of other
symptoms associated with dry mouth, six specific
100 mm VAS questions, including mouth dryness,
discomfort of the mouth, ability to sleep, abil-
ity to speak without drinking liquids, ability to
chew and swallow food, and ability to wear den-
tures, were also recorded at each visit. For these six
questions regarding conditions that may interfere
with a patient’s daily life, the response ranged from
0 mm (very dry, extremely uncomfortable and very
difficult, respectively) on the left to 100 mm (not
dry, comfortable and easy, respectively) on the
right. An increase of 25 mm or more above the
baseline score was defined as a response.
There were three questions that used a two-
point categorical response (yes or no) format to
tassess the condition of dry mouth within the las
3 days prior to the visits at weeks 6 and 12. These
questions evaluated whether study participants
had a more comfortable mouth or less dry mouth,
gor felt that it was easier to speak without drinkin
at weeks 6 and 12 after starting the study medica-
tion. The extent of use of oral comfort agents was
evaluated at the same time on the basis of three
rcategories of response (improved, no change, o
worse). For these categorical questions, patients
fwith improvement in symptoms or an answer o
“yes” were classified as responders, and those with
rno change or worsening of symptoms or an answe
of “no” were classified as nonresponders.
Saxon’s test20 with some modifications was
used to quantify saliva production. At each visit,
g subjects were first instructed to take nothin
by mouth for at least 90 minutes and then to
chew a piece of preweighed gauze for 5 minutes.
r The gauze was weighed again after chewing fo
5 minutes. The change in the weight of the gauze
grepresented the patient’s saliva production durin
this 5-minute period. After determination of the
predose saliva production, the study medication
was administered and the postdose saliva produc-
ftion was measured 60 minutes later. The effect o
the study medication on saliva production was
quantified by comparing the difference between
postdose and predose saliva production.
Safety
fSafety evaluations were based on the results o
physical examinations and ECG conducted before
tstudy entry, clinical laboratory tests conducted a
each visit and all reports of adverse experiences.
Vital signs were measured before each dose and
1 hour after taking the study medication at each
visit. During the 60-minute postdose period,
adverse experiences and dose tolerability were
queried. Adverse experiences were documented
throughout the study at each visit.
Statistical analysis
Statistical analysis was performed with Stata/SE
rversion 8.0 (Stata Corp., College Park, TX, USA) fo
Windows. Two-sided Fisher’s exact test was used to
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compare categorical data between the pilocarpine
and placebo groups. Wilcoxon’s rank sum test was
used to compare the VAS score and saliva pro-
duction between the two groups. Significance was
defined as a p value less than 0.05.
Results
Of 44 SS patients, 23 were randomized to the
pilocarpine group and 21 to the placebo group.
There was no significant difference in demographic
variables or disease characteristics between the
two groups (Table 1). The most frequently used
(>10%) medications were hydroxychloroquine
sulfate (200–400 mg/day), antacids, low dose
prednisolone (2.5–10 mg/day) and nonsteroidal
anti-inflammatory drugs. Use of these medica-
tions was similar between the pilocarpine and
placebo groups. There was a similar dropout rate
from the initial 44 patients, with 18 of 21 (85.7%)
in the placebo group and 16 of 23 (69.6%) in
the pilocarpine group completing the 3-month
study (p = 0.29; Table 2). In the placebo group,
one patient (4.8%) was lost to follow-up during
the period of severe acute respiratory syndrome
(SARS) outbreak in Taiwan and two patients
(9.6%) withdrew because of lack of efficacy. In
contrast, none of the 23 patients in the pilocarpine
group discontinued the study treatment due to
lack of efficacy. In the pilocarpine group, three
patients (13%) withdrew because of marked
sweating and four (17.4%) were lost to follow-up.
Of the four patients who were lost to follow-up,
two withdrew during the SARS outbreak period.
yThe reasons for discontinuation from the stud
were not significantly different between the pilo-
carpine and placebo groups (Table 2).
tGlobal assessment of xerostomia showed tha
a significant proportion of patients in the pilo-
carpine group (69.6%) had improvement in the
sensation of dry mouth compared to the placebo
group (23.8%) in the intention-to-treat analysis
(p = 0.0032; Figure 1). Patients taking pilocar-
pine four times daily also showed significant im-
provement in xerostomia-related conditions, such
tas ability to sleep and ability to speak withou
Table 1. Demographic and disease characteristics
of the study population*
Placebo Pilocarpine p
(n = 21) (n = 23)
Age (yr) 56.4 ± 12.5 57.1 ± 11.9 0.74
Female gender 17 (81.0) 22 (95.7) 0.18
Height (cm) 159.9 ± 5.5 157.3 ± 4.5 0.09
Weight (kg) 55.7 ± 9.3 53.1 ± 8.2 0.37
Rheumatic disease 1.00
Primary SS (%) 15 (71.4) 17 (73.9)
SLE (%) 2 (9.5) 2 (8.7)
*Data are presented as mean ± standard deviation or n (%).
SS = Sjögren’s syndrome; SLE = systemic lupus erythematosus.
Table 2. Patient disposition and reasons for
discontinuation in study population*
Placebo Pilocarpine p
(n = 21) (n = 23)
Completed study 18 (85.7) 16 (69.6) 0.29
Lack of efficacy 2 (9.5) 0 (0) 0.22
Adverse event† 0 (0) 3 (13.0) 0.23
Lost to follow-up‡ 1 (4.8) 4 (17.4) 0.35
*Data are presented as n (%); † tadverse event leading to dropou
of three patients taking pilocarpine was marked sweating; ‡two
of the four patients in the pilocarpine group withdrew during the
period of severe acute respiratory syndrome (SARS) outbreak in
Taiwan, and in the placebo group, the patient was lost to follow-
up during the SARS outbreak period.
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iF gure 1. f l l hComparison o  c inica  response in patients wit
Sjögren’s syndrome in the global assessment of dry mouth
(primary end point). At the end of the 12-week study, a
significant improvement in patients treated with pilocarpine
was noted compared to placebo (69.6% vs. 23.8%,
p = 0.0032).
C.H. Wu, et al
800 J Formos Med Assoc | 2006 • Vol 105 • No 10
drinking liquids (Figure 2). Borderline signifi-
cance (p = 0.07) in the ability to chew and swal-
low was observed in the pilocarpine group
compared to the placebo group. Three patients
in the placebo group and four in the pilocarpine
group were denture wearers, but none of the
patients in either group had significant improve-
ment in the ability to wear dentures. However,
analysis of VAS scores between the pilocarpine and
placebo groups indicated a significant improve-
ment (p < 0.01) in the pilocarpine group in five of
six specific dry mouth symptoms, including mouth
dryness, mouth comfort, ability to sleep, ability
to speak and ability to swallow food (all p < 0.01)
compared to baseline.
In addition to improved VAS scores, patients
rin the pilocarpine group also reported greate
mouth comfort, less dryness and found it easier to
speak compared to the placebo group (Figure 3).
Although four patients in the pilocarpine group
(17.4%) vs. placebo group (0%) experienced re-
duced use of oral comfort agents, the difference
did not reach significance (p = 0.11).
fSaliva secretion was evaluated in the unit o
g/minute and any increase in saliva flow more
than baseline secretion was defined as a response.
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iF gure 2. f h f h ’ d h l lComparison o  t e percentage o  patients wit  Sjögren s syn rome s owing c inica  improvement in symptoms
associated with dry mouth in questionnaire responses. The pilocarpine group demonstrated significant differences in
symptomatic relief of oral symptoms in mouth dryness, mouth comfort, ability to sleep and ability to speak without
drinking liquids. For the ability to chew and swallow food, a borderline significance was observed in the pilocarpine group
compared with the placebo group. An increase of 25 mm or more above the baseline score of these 100 mm visual analog
scale questions was defined as response.
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iF gure 3. f ’ d h d h d l dPercentage o  Sjögren s syn rome patients wit  a response in ry mout  symptoms an  in sa iva pro uction at
the end points. A greater proportion of patients in the pilocarpine group responded to therapy compared to the placebo
group by the experience of more comfortable and less dry mouth, improved ability to speak and an increase in saliva produc-
tion at the 60-minute postdose collection at the end of the study. No significant difference in decreased use of oral comfort
agents between the two groups was observed.
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At the end of the study, patients in the pilocarpine
group exhibited a higher response (65.2%) in
60-minute postdose saliva production than the
placebo group (28.6%) in the intention-to-treat
analysis (p=0.02; Figure 3). The median increase in
saliva production in the pilocarpine group was also
significantly greater than that in the placebo group
(0.05 g/minute vs. −0.02 g/minute, p = 0.0014) at
12 weeks. A significant response in global assess-
ment of xerostomia, symptoms associated with dry
mouth and saliva secretion in the pilocarpine
group was observed throughout the study period.
No serious adverse event was found during the
study. Five patients (21.7%) in the pilocarpine
group experienced perspiration and three of them
withdrew from the study. Palpitation was reported
in two patients, one (4.3%) in the pilocarpine
group and the other (4.8%) in the placebo group.
Most of the participants tolerated the study med-
ication. No significant alterations in blood pres-
sure, heart rate, hematopoietic, renal or hepatic
profiles were noted during the study.
Discussion
This study demonstrated the clinical efficacy and
safety of pilocarpine 5 mg four times daily for the
treatment of dry mouth in patients with SS in
Taiwan. As ethnicity can act as a predictor of the
treatment outcome of a disease,21 separate clini-
cal trials to determine the treatment response of
patients with dry mouth to pilocarpine need to
be performed in different races. In this study, 
patients with SS in Taiwan who received pilocarpine
experienced global improvement of xerostomia,
significant improvement in most of the symp-
toms associated with dry mouth including mouth
dryness, mouth comfort, ability to sleep, ability
to speak, and ability to swallow food, and an
increase in saliva secretion from baseline without
serious adverse effects and drug–drug interactions.
Although the sample size was small, this study
demonstrated the treatment benefits of pilocarpine
in patients with SS in Taiwan. Further study with a
larger sample size is needed. The lack of significant
difference in improved ability to swallow and to
wear dentures, and in decreased use of oral agents
ybetween the pilocarpine and placebo groups ma
be due to the relatively small sample size. These
differences might become significant only with a
higher case number.
In a fixed dose trial by Vivino et al12 and a dose
titration study by PaPas et al,22 pilocarpine at doses
of 20 mg/day or higher for 12 weeks resulted in
significant global improvement in dry mouth as
well as dry eyes. Furthermore, increase in saliva
flow was also noted through the dosing interval
at 60 minutes. We did not evaluate the clinical
effect of pilocarpine on dry eyes because our pur-
f pose was to evaluate the efficacy and safety o
pilocarpine for the treatment of xerostomia in
patients with SS in Taiwan. It has been demon-
strated that treatment with pilocarpine at doses
of 20 mg/day or higher in patients with SS re-
sulted not only in improvement in symptoms
and signs of intraoral dryness but also alleviation
of other sicca manifestations, such as dry eyes,
dry skin, vaginal dryness and other xeroses.10,12,22
Indeed, a recent randomized controlled study also
confirmed the beneficial effect of 12-week oral
pilocarpine on ocular symptoms in patients with
SS.23 Ethnicity does not appear to affect the treat-
ment efficacy of pilocarpine tablets on patients
with SS among Caucasians, Orientals, Blacks and
other origins, as this trial and other studies12,22,24
all demonstrated that pilocarpine therapy bene-
fited patients with SS by improving the symp-
toms of xerostomia.
In SS, the deficient secretory response of sali-
vary and lacrimal glands leading to dry mouth and
dry eyes is attributed to both a decrease in the
fnumber of secretory units and a dysfunction o
the residual secretory units.25 Despite dysfunction,
the residual glandular elements in these exocrine
glands preserve their neural innervation26 and have
upregulation of muscarinic receptors.27 Therefore,
the excess of muscarinic receptors in the exocrine
glands provides a target for the therapeutic use of a
secretagogue to stimulate secretion from exocrine
glands in patients with SS.8,13 tIt is conceivable tha
the physiologic roles and the protective functions
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of saliva include lubrication, digestion, phonation,
mastication, remineralization, maintenance of
balance of oral microflora, buffer activity, and
immunity and defense. Hence, the administra-
tion of a secretagogue like pilocarpine to stimulate
saliva production is preferred to the use of a saliva
substitute for the treatment of dry mouth in SS
patients.2,12,28
Pilocarpine is a cholinergic parasympathomi-
metic agonist that binds to muscarinic-M3 recep-
tors of various exocrine glands for stimulation of
secretory function.13 According to the pharmacoki-
netic profile of this drug, its effect on saliva flow
is dose-dependent and time-related, with a peak
effect at 1 hour and a duration of 3–5 hours.29
Therefore, optimal benefit can be achieved with
a four times daily dosing regimen. However, the
cholinergic activity of this drug also contributes to
its adverse effects in patients with SS, such as
sweating, urinary frequency and flushing.10,12,22
In fact, sweating is the most common drug-related
adverse event (up to 43%) and could be a major
reason for withdrawal from study.12 But in gen-
eral, these adverse events tend to decrease over
time and might be diminished by starting with a
low dose (e.g. 5mg once or twice daily), and then
increasing the dose gradually until the mainte-
nance dose of 5 mg four times daily is achieved.2,23
Due to the high efficacy and safety, stimulation
of saliva flow with a secretagogue is now consid-
ered to be the treatment of choice for symptomatic
relief of the sicca syndrome and has become the
most effective medication to prevent dental and
oral complications in patients with SS.2,3,10,12
In conclusion, the results of this study suggest
that pilocarpine 5 mg four times daily for 12 weeks
is effective, safe and well tolerated for the relief of
oral symptoms in patients with SS in Taiwan. The
most frequent adverse event was sweating, but it
did not increase the treatment withdrawal rate.
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